Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Deal With Vertex, NYSE Listing Bolster U.S. Presence

Executive Summary

Novartis has augmented its U.S. research profile with a long-term drug discovery deal with Cambridge, Mass.-based Vertex Pharmaceuticals.

You may also be interested in...



Merck Adds To Cancer Research Aura With Vertex Aurora Kinase Inhibitors

Merck and Vertex expect to begin clinical trials of the aurora kinase inhibitor anticancer agent VX-680 during the second half of the year

Merck Adds To Cancer Research Aura With Vertex Aurora Kinase Inhibitors

Merck and Vertex expect to begin clinical trials of the aurora kinase inhibitor anticancer agent VX-680 during the second half of the year

Novartis Rx Exec Changes Include U.S. COO Epstein To Oncology Unit Head

Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.

Related Content

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel